Alexandria Real Estate Equities Announces Key Milestone in Depression Precision Medicine Initiative
Alexandria Real Estate Equities (NYSE: ARE) has reached a foundational milestone with the Foundation for the National Institutes of Health (FNIH), completing the critical design phase of its Multi-Modal Assessment and Phenotyping in Depression (MAP-D) initiative. This marks progress toward a first-of-its-kind clinical study aimed at redefining how major depressive disorder is diagnosed and treated through precision medicine. The MAP-D initiative, launched with Alexandria's initial funding and strategic partnership with the FNIH, seeks to identify biological signatures of depression that can lead to more personalized treatment approaches. The project aims to improve outcomes for millions by enabling better diagnosis and accelerating therapy development using advanced artificial intelligence models. Alexandria is recognized as a founding partner in this public-private initiative, which has already received the prestigious Charles A. Sanders Partnership Award from FNIH. The study will begin with a $22 million pilot phase over three years, potentially expanding into an effort exceeding $70 million.
Tickers: $ARE